The stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy

Hepatology

Volumn 58, Issue 3, 2013, Pages 1122-1132

  Bajaj, Jasmohan S ^a   Thacker, Leroy R ^a   Heuman, Douglas M ^a   Fuchs, Michael ^a   Sterling, Richard K ^a   Sanyal, Arun J ^a   Puri, Puneet ^a   Siddiqui, Mohammad S ^a   Stravitz, Richard T ^a   Bouneva, Iliana ^a   Luketic, Velimir ^a   Noble, Nicole ^a   White, Melanie B ^a   Monteith, Pamela ^a   Unser, Ariel ^a   Wade, James B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; GOLD STANDARD; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; STROOP SMARTPHONE APPLICATION; STROOP TEST; TEST RETEST RELIABILITY;

CASE-CONTROL STUDIES; CELLULAR PHONE; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84883235783     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26309     Document Type: Article

References (30)

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-721.
2. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology 2009;50:2014-2021.
3. Bajaj JS, Saeian K, Schubert CM, Hafeezullah M, Franco J, Varma RR, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009;50:1175-1183.
4. Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance, and recommendations. J Hepatol 2005;42(Suppl):S45-S53.
5. Soriano G, Roman E, Cordoba J, Torrens M, Poca M, Torras X, et al. Cognitive dysfunction in cirrhosis is associated with falls: a prospective study. Hepatology 2012;55:1922-1930.
6. Dhiman RK, Kurmi R, Thumburu KK, Venkataramarao SH, Agarwal R, Duseja A, Chawla Y. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci 2010;55:2381-2390.
7. Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011;140:478-487.e471.
8. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549-559.
9. Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2012;27:1329-1335.
10. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011;106:307-316.
11. Bajaj JS, Etemadian A, Hafeezullah M, Saeian K. Testing for minimal hepatic encephalopathy in the United States: An AASLD survey. Hepatology 2007;45:833-834.
12. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34:768-773.
13. Amodio P, Schiff S, Del Piccolo F, Mapelli D, Gatta A, Umilta C. Attention dysfunction in cirrhotic patients: an inquiry on the role of executive control, attention orienting, and focusing. Metab Brain Dis 2005;20:115-127.
14. Felipo V, Ordono JF, Urios A, El Mlili N, Gimenez-Garzo C, Aguado C, et al. Patients with minimal hepatic encephalopathy show impaired mismatch negativity correlating with reduced performance in attention tests. Hepatology 2012;55:530-539.
15. Company L, Zapater P, Perez-Mateo M, Jover R. Extrapyramidal signs predict the development of overt hepatic encephalopathy in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2010;22:519-525.
16. Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, Mapelli D, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009;29:629-635.
17. Bajaj JS, Hafeezullah M, Franco J, Varma RR, Hoffmann RG, Knox JF, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008;135:1591-1600.e1591.
18. Amodio P, Ridola L, Schiff S, Montagnese S, Pasquale C, Nardelli S, et al. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology 2010;139:510-518, 518.e511-512.
19. Romero-Gomez M, Cordoba J, Jover R, del Olmo JA, Ramirez M, Rey R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007;45:879-885.
20. Posner MI, Petersen SE. The attention system of the human brain. Annu Rev Neurosci 1990;13:25-42.
21. Cordoba J. New assessment of hepatic encephalopathy. J Hepatol 2011;54:1030-1040.
22. Weissenborn K, Giewekemeyer K, Heidenreich S, Bokemeyer M, Berding G, Ahl B. Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis 2005;20:359-367.
23. Zhang LJ, Yang G, Yin J, Liu Y, Qi J. Neural mechanism of cognitive control impairment in patients with hepatic cirrhosis: a functional magnetic resonance imaging study. Acta Radiol 2007;48:577-587.
24. Riggio O, Ridola L, Pasquale C, Nardelli S, Pentassuglio I, Moscucci F, Merli M. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2010;9:181-183.
25. Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010;138:2332-2340.
26. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY; International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011;33:739-747.
27. Sorrell JH, Zolnikov BJ, Sharma A, Jinnai I. Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation. Psychiatry Clin Neurosci 2006;60:174-181.
28. Bajaj JS, Ahluwalia V, Wade JB, Sanyal AJ, White MB, Noble NA, et al. Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis. J Hepatol 2013;58:38-44.
29. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012;55:1164-1171.
30. Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy-a decision analysis. Aliment Pharmacol Ther 2007;26:1147-1161.